Nathan Ford

Summary

Publications

  1. ncbi Public health and company wealth
    Nathan Ford
    , London EC1N 8QX
    BMJ 326:1296. 2003
  2. ncbi Mortality, violence and lack of access to healthcare in the Democratic Republic of Congo
    Michel van Herp
    Disasters 27:141-53. 2003
  3. ncbi Sustaining access to antiretroviral therapy in the less-developed world: lessons from Brazil and Thailand
    Nathan Ford
    Medecins Sans Frontieres, 522 Mooban Nakorn Thai 14, Ladphrao Soi 101 1, Bangkok 10240, Thailand
    AIDS 21:S21-9. 2007
  4. ncbi The role of civil society in protecting public health over commercial interests: lessons from Thailand
    Nathan Ford
    , Ladphrao, Klongchan Bangkapi, Bangkok, Thailand
    Lancet 363:560-3. 2004
  5. ncbi Registration problems for antiretrovirals in Africa
    Nathan Ford
    , Khayelitsha, 7784 South Africa
    Lancet 367:794-5. 2006
  6. ncbi Challenge and co-operation: civil society activism for access to HIV treatment in Thailand
    Nathan Ford
    Medecins Sans Frontieres, Bangkok, Thailand
    Trop Med Int Health 14:258-66. 2009
  7. ncbi HIV-1 viral load monitoring: an opportunity to reinforce treatment adherence in a resource-limited setting in Thailand
    David Wilson
    Medecins Sans Frontieres, Ladphrao, Bangkok, Thailand
    Trans R Soc Trop Med Hyg 103:601-6. 2009
  8. ncbi HIV prevention, care, and treatment in two prisons in Thailand
    David Wilson
    , Bangkapi, Bangkok, Thailand
    PLoS Med 4:e204. 2007
  9. ncbi WHO must defend patients' interests, not industry
    Paul Cawthorne
    , Bangkok 10240, Thailand
    Lancet 369:974-5. 2007
  10. ncbi Addressing psychosocial needs in the aftermath of the tsunami
    Kaz de Jong
    PLoS Med 2:e179. 2005

Collaborators

Detail Information

Publications65

  1. ncbi Public health and company wealth
    Nathan Ford
    , London EC1N 8QX
    BMJ 326:1296. 2003
  2. ncbi Mortality, violence and lack of access to healthcare in the Democratic Republic of Congo
    Michel van Herp
    Disasters 27:141-53. 2003
    ..Infectious-disease control and treatment are a priority, as is increasing access to health-care. Humanitarian assistance must be increased considerably, especially in rural areas and zones that have been affected directly by conflict...
  3. ncbi Sustaining access to antiretroviral therapy in the less-developed world: lessons from Brazil and Thailand
    Nathan Ford
    Medecins Sans Frontieres, 522 Mooban Nakorn Thai 14, Ladphrao Soi 101 1, Bangkok 10240, Thailand
    AIDS 21:S21-9. 2007
    ..An informed and engaged civil society is essential to support governments in putting health before trade...
  4. ncbi The role of civil society in protecting public health over commercial interests: lessons from Thailand
    Nathan Ford
    , Ladphrao, Klongchan Bangkapi, Bangkok, Thailand
    Lancet 363:560-3. 2004
  5. ncbi Registration problems for antiretrovirals in Africa
    Nathan Ford
    , Khayelitsha, 7784 South Africa
    Lancet 367:794-5. 2006
  6. ncbi Challenge and co-operation: civil society activism for access to HIV treatment in Thailand
    Nathan Ford
    Medecins Sans Frontieres, Bangkok, Thailand
    Trop Med Int Health 14:258-66. 2009
    ..Today, most PHA in Thailand can access treatment, and efforts have shifted to supporting care for excluded populations...
  7. ncbi HIV-1 viral load monitoring: an opportunity to reinforce treatment adherence in a resource-limited setting in Thailand
    David Wilson
    Medecins Sans Frontieres, Ladphrao, Bangkok, Thailand
    Trans R Soc Trop Med Hyg 103:601-6. 2009
    ..When implemented with a patient-centered approach, it can be a very useful tool for psychosocial support...
  8. ncbi HIV prevention, care, and treatment in two prisons in Thailand
    David Wilson
    , Bangkapi, Bangkok, Thailand
    PLoS Med 4:e204. 2007
  9. ncbi WHO must defend patients' interests, not industry
    Paul Cawthorne
    , Bangkok 10240, Thailand
    Lancet 369:974-5. 2007
  10. ncbi Addressing psychosocial needs in the aftermath of the tsunami
    Kaz de Jong
    PLoS Med 2:e179. 2005
  11. ncbi Lessons learned during down referral of antiretroviral treatment in Tete, Mozambique
    Tom Decroo
    South African Medical Unit, Medecins Sans Frontieres, Johannesburg, South Africa
    J Int AIDS Soc 12:6. 2009
    ..Down referral can be avoided by initiating patients' antiretroviral treatment at clinic level from the outset...
  12. ncbi Do aid agencies have an ethical duty to comply with researchers? A response to Rennie
    Rony Zachariah
    Medecins Sans Frontieres, 68 Rue de Gasperich, L 1617, Gasperich, Luxembourg
    Dev World Bioeth 6:78-80. 2006
    ....
  13. ncbi Ethics of conducting research in conflict settings
    Nathan Ford
    , Johannesburg, South Africa
    Confl Health 3:7. 2009
    ..Special attention needs to be placed on the feasibility and necessity of doing research in conflict-settings, and the harm-benefit ratio for potential research participants...
  14. ncbi An integrated approach of community health worker support for HIV/AIDS and TB care in Angónia district, Mozambique
    Sandrine Simon
    , Maputo, Mozambique
    BMC Int Health Hum Rights 9:13. 2009
    ..CONCLUSION: The community health team has several advantages over 'disease-specific' community health worker approaches in terms of accountability, acceptability, and expanded access to care...
  15. ncbi Renal safety of a tenofovir-containing first line regimen: experience from an antiretroviral cohort in rural Lesotho
    Helen Bygrave
    Medecins Sans Frontieres, Morija, Lesotho
    PLoS ONE 6:e17609. 2011
    ..We report prevalence of abnormal renal function at baseline and factors associated with abnormal renal function from a community cohort in Lesotho...
  16. ncbi Implementing a tenofovir-based first-line regimen in rural Lesotho: clinical outcomes and toxicities after two years
    Helen Bygrave
    Medecins Sans Frontieres, Morija, Lesotho
    J Acquir Immune Defic Syndr 56:e75-8. 2011
    ..We report on outcomes and toxicities among patients on these different regimens in a routine treatment cohort in Lesotho...
  17. ncbi Early initiation of antiretroviral therapy and associated reduction in mortality, morbidity and defaulting in a nurse-managed, community cohort in Lesotho
    Nathan Ford
    Medecins Sans Frontieres, University of Cape Town, South Africa
    AIDS 24:2645-50. 2010
    ..Lesotho has supported earlier initiation since 2008. We assessed outcomes comparing early (CD4 cell counts >200 cells/?l) and late (CD4 cell counts ?200 cells/?l) initiation...
  18. ncbi Operative mortality in resource-limited settings: the experience of Medecins Sans Frontieres in 13 countries
    Kathryn M Chu
    Department of Surgery, Johns Hopkins Medical Institutions, Baltimore, Maryland, USA
    Arch Surg 145:721-5. 2010
    ..To determine operative mortality in surgical programs from resource-limited settings...
  19. ncbi Early adherence to antiretroviral medication as a predictor of long-term HIV virological suppression: five-year follow up of an observational cohort
    Nathan Ford
    Medecins Sans Frontieres, Cape Town, South Africa
    PLoS ONE 5:e10460. 2010
    ..Previous studies have demonstrated a cross-sectional relationship between antiretroviral adherence and HIV virological suppression. We assessed the predictive value of baseline adherence in determining long-term virological failure...
  20. ncbi Safety of efavirenz in first-trimester of pregnancy: a systematic review and meta-analysis of outcomes from observational cohorts
    Nathan Ford
    Medecins Sans Frontieres, University of Cape Town, Cape Town, South Africa
    AIDS 24:1461-70. 2010
    ..Data on efavirenz safety in first trimester pregnancy are conflicting. We conducted a systematic review and meta-analysis of the available evidence from observational cohorts...
  21. ncbi Slow response to Angola's food crisis
    Nathan Ford
    , 124-32 Clerkenwell Road, London EC1R 5DJ, UK
    Lancet 360:334-6. 2002
  22. ncbi Directly observed antiretroviral therapy: a systematic review and meta-analysis of randomised clinical trials
    Nathan Ford
    Medecins Sans Frontieres, Cape Town, Western Cape, South Africa
    Lancet 374:2064-71. 2009
    ..We did a systematic review and meta-analysis of randomised trials of directly observed versus self-administered antiretroviral treatment...
  23. ncbi Improving first-line antiretroviral therapy in resource-limited settings
    Nathan Ford
    Medecins Sans Frontieres, Medical Unit, Cape Town, South Africa
    Curr Opin HIV AIDS 5:38-47. 2010
    ..Newer medicines with greater potency and better safety profiles open the possibility for improving first-line antiretroviral therapy for developing countries...
  24. ncbi The first decade of antiretroviral therapy in Africa
    Nathan Ford
    Medecins Sans Frontieres, Geneva, Switzerland
    Global Health 7:33. 2011
    ....
  25. ncbi Nevirapine-associated early hepatotoxicity: incidence, risk factors, and associated mortality in a primary care ART programme in South Africa
    Kathryn M Chu
    South African Medical Unit, Medecins Sans Frontieres, Johannesburg, South Africa
    PLoS ONE 5:e9183. 2010
    ..One of the primary concerns with the use of this regimen is nevirapine-associated hepatotoxicity...
  26. ncbi Surgical care for the direct and indirect victims of violence in the eastern Democratic Republic of Congo
    Kathryn Chu
    Medecins Sans Frontieres, 49 Jorrisen St, Braamfontein 2017, Johannesburg, South Africa
    Confl Health 4:6. 2010
    ..In this paper we report on surgical interventions carried out by Médecins sans Frontières in Masisi, North Kivu, Democratic Republic of Congo to contribute to the scarce evidence base on surgical needs in conflict...
  27. ncbi When to start antiretroviral therapy in resource-limited settings: a human rights analysis
    Nathan Ford
    Medecins Sans Frontieres, Cape Town, South Africa
    BMC Int Health Hum Rights 10:6. 2010
    ....
  28. ncbi Implementing antiretroviral therapy in rural communities: the Lusikisiki model of decentralized HIV/AIDS care
    Martha Bedelu
    Medecins Sans Frontieres, Lusikisiki, South Africa
    J Infect Dis 196:S464-8. 2007
    ..Maintaining quality and coverage will require increased resource input from the public sector and full acceptance of creative approaches to implementation, including task shifting and community involvement...
  29. ncbi International nurse migration and HIV/AIDS
    Sharonann Lynch
    JAMA 300:1024; author reply 1024. 2008
  30. ncbi HIV treatment in a conflict setting: outcomes and experiences from Bukavu, Democratic Republic of the Congo
    Heather Culbert
    , Amsterdam, The Netherlands
    PLoS Med 4:e129. 2007
  31. ncbi Access to drugs: the case of Abbott in Thailand
    Paul Cawthorne
    Lancet Infect Dis 7:373-4. 2007
  32. ncbi Cytomegalovirus retinitis: the neglected disease of the AIDS pandemic
    David Heiden
    Department of Ophthalmology and Pacific Vision Foundation, California Pacific Medical Center, San Francisco, California, United States of America
    PLoS Med 4:e334. 2007
  33. ncbi Treating HIV in the developing world: getting ahead of the drug development curve
    Nathan Ford
    Drug Discov Today 12:1-3. 2007
  34. ncbi The courage to change the rules: a proposal for an essential health R&D treaty
    Nicoletta Dentico
    PLoS Med 2:e14. 2005
  35. ncbi Violence in southern Sudan
    Vincent Brown
    Epicentre, 8 rue Saint Sabin, 75 011 Paris, France
    Lancet 359:161. 2002
  36. ncbi HIV drug resistance
    Alexandra Calmy
    N Engl J Med 350:2720-1. 2004
  37. ncbi 25 years of the WHO essential medicines lists: progress and challenges
    Richard Laing
    Boston University School of Public Health, Boston, MA 02118, USA
    Lancet 361:1723-9. 2003
    ..This approach has required an engagement by WHO on issues such as the effect of international trade agreements on access to essential medicines and research and development to ensure availability of new essential medicines...
  38. ncbi The G8 and access to medicines: no more broken promises
    Mary Moran
    , EC1N 8QX, London, UK
    Lancet 361:1578-9. 2003
  39. ncbi WHO must continue its work on access to medicines in developing countries
    Nathan Ford

    Lancet 361:3. 2003
  40. ncbi Rapid assessment of mortality and malnutrition in Afghanistan
    Patrice Piola
    JAMA 288:1233-4. 2002
  41. ncbi HIV/AIDS prevention and treatment
    Eric Goemaere
    Lancet 360:86-7; author reply 87-8. 2002
  42. ncbi The tenofovir pre-exposure prophylaxis trial in Thailand: researchers should show more openness in their engagement with the community
    Arlene Chua
    PLoS Med 2:e346. 2005
  43. ncbi HIV viral load monitoring in resource-limited regions: optional or necessary?
    Alexandra Calmy
    Medecins Sans Frontieres, Access to Medicines Campaign, Geneva, 1211, Switzerland
    Clin Infect Dis 44:128-34. 2007
    ..Rather than considering viral load data to be an unaffordable luxury, efforts should be made to ensure that viral load testing becomes affordable, simple, and easy to use in resource-limited settings...
  44. ncbi (The Lancet)red: a missed opportunity
    Alexandra Calmy
    Lancet 368:1063. 2006
  45. ncbi Scaling up antiretroviral treatment in resource-poor settings
    Tom Ellman
    Lancet 368:445-6. 2006
  46. ncbi Generic fixed-dose combination antiretroviral treatment in resource-poor settings: multicentric observational cohort
    Alexandra Calmy
    MSF, Campaign for Access to Essential Medicines, 78 rue de Lausanne, 1205 Geneva, Switzerland
    AIDS 20:1163-9. 2006
    ..The use fixed-dose combination (FDC) is a critical tool in improving HAART. Studies on the effectiveness of combined lamivudine, stavudine and nevirapine (3TC/d4T/NVP) are scarce...
  47. ncbi Discussions in Geneva, demonstrations in Delhi: why incentives for drug innovation need reviewing
    Nathan Ford
    Drug Discov Today 12:349-51. 2007
  48. ncbi First round of payments from the Global Fund
    Tom Ellman
    Lancet 360:262. 2002
  49. ncbi XDR-TB in South Africa: detention is not the priority
    Eric Goemaere
    PLoS Med 4:e162. 2007
  50. ncbi Drug development for neglected diseases: a deficient market and a public-health policy failure
    Patrice Trouiller
    Centre Hospitalier Universitaire, BP 217, 38043 Grenoble Cedex 9, France
    Lancet 359:2188-94. 2002
    ..Private-sector research obligations should be explored, and a public-sector not-for-profit research and development capacity promoted...
  51. ncbi Psychological trauma of the civil war in Sri Lanka
    Kaz de Jong
    , Amsterdam, Netherlands
    Lancet 359:1517-8. 2002
  52. ncbi Generic medicines are not substandard medicines
    Nathan Ford
    Lancet 359:1351; author reply 1351-2. 2002
  53. ncbi Conflict in Sri Lanka. Sri Lanka's health service is a casualty of 20 years of war
    Brigg Reilley
    , Colombo, Sri Lanka
    BMJ 324:361. 2002
  54. ncbi Malaria: current status of control, diagnosis, treatment, and a proposed agenda for research and development
    Philippe J Guerin
    Norwegian Institute of Public Health, Norway
    Lancet Infect Dis 2:564-73. 2002
    ..Evidence on these approaches should provide national governments and international donors with the cost-benefit information that would justify much-needed increases in global support for appropriate and effective malaria control...
  55. ncbi Trade concerns must not be allowed to set the public health agenda
    Nathan Ford
    Lancet 361:71-2. 2003
  56. ncbi Scaling up of highly active antiretroviral therapy in a rural district of Malawi: an effectiveness assessment
    Laurent Ferradini
    Epicentre, Paris, France
    Lancet 367:1335-42. 2006
    ..We aimed to assess the effectiveness of such a programme held by Médecins Sans Frontières (MSF) in the Chiradzulu district, Malawi...
  57. ncbi Treatment of neuropathic pain in Sierra Leone
    Phillipe Lacoux
    Ninewells Hospital and Medical School, Dundee DD1 9SY, Scotland, UK
    Lancet Neurol 1:190-5. 2002
    ..There have recently been no major treatment advances for neuropathic or phantom pain; however, the general body of knowledge about amputation pain can be increased by observations from these difficult settings...
  58. ncbi DFID's health strategy
    Gorik Ooms
    Lancet 370:652-3. 2007
  59. ncbi Trauma of Chechnya's ongoing war on internally displaced people
    Kaz de Jong
    Lancet 364:1008. 2004
  60. ncbi Effectiveness of highly active antiretroviral therapy in HIV-positive children: evaluation at 12 months in a routine program in Cambodia
    Bart Janssens
    Medecins Sans Frontieres, Phnom Penh, Cambodia
    Pediatrics 120:e1134-40. 2007
    ..We aimed to describe the clinical, immunologic, and virologic outcomes of pediatric patients with >12 months of highly active antiretroviral therapy in 2 routine programs in Cambodia...
  61. ncbi HIV and cytomegalovirus in Thailand
    Arlene Chua
    Lancet Infect Dis 5:328-9. 2005
  62. ncbi When best practice is bad medicine: a new approach to rationing tertiary health services in South Africa
    Chris Kenyon
    Division of Infectious Diseases and HIV Medicine at Groote Schuur Hospital, Cape Town
    S Afr Med J 98:350, 352, 354 passim. 2008
  63. ncbi How developing world concerns need to be part of drug development plans: a case study of four emerging antiretrovirals
    Jens Van Roey
    Medecins Sans Frontieres, Campaign for Access to Essential Medecins, Rue de Lausanne 78, 1211 Geneva, Switzerland
    Drug Discov Today 13:601-5. 2008
    ..Key research questions relevant for developing countries need to be answered early in the drug development process to ensure maximum benefit for the majority...
  64. ncbi First-line and second-line antiretroviral therapy
    Alexandra Calmy
    Lancet 364:329; author reply 330. 2004